Paradoxical reaction to etanercept: Development of pyoderma gangraenosum during therapy of psoriasis arthritis;Paradoxe Reaktion auf Etanercept: Entwicklung eines Pyoderma gangraenosum unter Therapie wegen Psoriasis-Arthritis

JDDG - Journal of the German Society of Dermatology

Volumn 11, Issue 5, 2013, Pages 447-449

  Kowalzick, Lutz ^a   Bertolini, Julia ^b   Baumann, Christine ^c   Walther, Beate ^a   Truhm, Beate ^a   Eickenscheidt, Lena ^a  

^a Childrens Hospital   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c Practice for Internal Medicine and Rheumatology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; DICLOFENAC; ETANERCEPT; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ADULT; CASE REPORT; COLITIS; COLON BIOPSY; COLONOSCOPY; CORTICOSTEROID THERAPY; DIARRHEA; DISEASE ACTIVITY; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; PARADOXICAL DRUG REACTION; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PYODERMA GANGRENOSUM; SKIN BIOPSY; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; PYODERMA GANGRENOSUM; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84877137094     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/ddg.12032     Document Type: Letter

References (11)

1. Charles CA, Leon A, Banta MR, Kirsner RS. Etanercept for the treatment of refractory pyoderma gangraenosum: a brief series. Int J Dermatol 2007; 46: 10959.
2. Giamerellos-Bourboulis EJ, Pelekanou E, Antopoulou A, Petropoulou H, Baziaka F, Karagini V, Stavrianeas N, Giamarellou H. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Brit J Dermatol 2008; 158: 56772.
3. Siroy A, Warsman J. Metastatic Crohn Disease: a rare cutaneous entity. Arch Pathol Lab Med 2012; 136: 32932.
4. Oh J, Arkfeld DG, Horwitz DA. Development of Crohns disease in a patient taking etanercept. J Rheumatol 2005; 32: 7523.
5. Freeman HJ. Colitis associated with biological agents. World J Gastroentereol 2012; 18: 18714.
6. Fouache D, Goéb V, Massy-Guillement N, Avenel G, Bacquet- Deschryver H, Kozyreff-Meurice M, Ménard JF, Muraine M, Savoye G, Le Loét X, Tharasse C, Vittecoq O. Paradoxical adverse events of anti-tumor necrosis factor therapy for spondylarthropathies: a retrospective study. Rheumatology 2009; 48: 7614.
7. Jamez-López N, Molina V, Arroyave JE, Vasquez LA, Ruiz AC, Castaño R, Ruiz MH. Developement of pyoderma gangraenosum during therapy with infliximab. J Dermatol Case Rep 2009; 3: 203.
8. Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: a way to treat the trigger? Acta Derm Venereol 2010; 90: 1835.
9. Stichenwirth M, Riedel E, Pehamberger H, Tappeiner G. Pyoderma gangraenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimunmab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon? Arch Dermatol 2008; 144: 8178.
10. Zaghi D, Krueger GG, Callis Duffin K. Ustekinumab: a review in the treatment of plaque psoriasis and peoriatic arthritis. J Drugs Dermatol 2012; 11: 1607.
11. Genova E, Teska A, Fehrenbacher B, Hoerber S, Adamzcyk A, Schaller M, Hoetzenecker W, Biedermann T. Interleukin 23 expression in pyoderma gagraenosum and targeted therapy with ustekinumab. Arch Dermatol 2011; 147: 12035.